Ferring Pharmaceuticals today announced that Aaron Graff has been appointed Chief Executive Officer of Ferring Holding Inc.
In this role Mr. Graff assumes direct responsibility for all Ferring US activities including commercial operations (Ferring Pharmaceuticals Inc.), clinical development (Ferring International PharmaScience Center US), and manufacturing (Ferring Production Inc.).
“A US-based CEO helps ensure that important decisions concerning the US business benefit from the insight that only close proximity to the market provides,” comments Mr. Graff.
As CEO, Mr. Graff reports to the board of directors of Ferring Holding Company Inc., chaired by Michel Pettigrew, President of the Executive Board and Chief Operating Officer, Ferring Group.
Since joining Ferring Pharmaceuticals Inc. as President and Chief Operating Officer in 2010, Mr. Graff has overseen consistent double-digit annual growth in the US subsidiary and the expansion of its US presence to include an integrated operations center. This center, located in Parsippany, New Jersey, includes product development, manufacturing, commercial and all necessary medical, regulatory, and support functions.
Originally from Niagara Falls, New York, Mr. Graff joined Ferring in 2002 as Vice President, Global Marketing and Business Development based in Denmark. He later became Senior Vice President, Asia Region and Global Marketing based at the company’s global headquarters in Switzerland.
Prior to joining Ferring, Mr. Graff worked for over 17 years at Bristol-Myers Squibb in both the USA and Europe. His responsibilities included a broad variety of commercial positions in prescription pharmaceuticals and non-prescription medicines.
Source: Ferring Pharmaceuticals Inc.
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
